These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

188 related items for PubMed ID: 34586526

  • 1. An open-label, prospective, single-arm study of switching from infliximab to cyclosporine for refractory uveitis in patients with Behçet's disease in long-term remission.
    Ida Y, Takeuchi M, Ishihara M, Shibuya E, Yamane T, Hasumi Y, Kawano S, Kimura I, Mizuki N.
    Jpn J Ophthalmol; 2021 Nov; 65(6):843-848. PubMed ID: 34586526
    [Abstract] [Full Text] [Related]

  • 2. Long-term outcomes of infliximab in patients with Behçet's disease-associated uveitis.
    Yamana S, Hasegawa E, Takeda A, Yawata N, Sonoda KH.
    Int Ophthalmol; 2023 Mar; 43(3):937-944. PubMed ID: 36057758
    [Abstract] [Full Text] [Related]

  • 3. Infliximab therapy in Behçet's uveitis.
    Alizadegan F, Yalcinbayir O, Ucan Gunduz G, Pehlivan Y.
    J Fr Ophtalmol; 2022 Nov; 45(9):1036-1041. PubMed ID: 36150991
    [Abstract] [Full Text] [Related]

  • 4. Comparative Study of Infliximab Versus Adalimumab in Refractory Uveitis due to Behçet's Disease: National Multicenter Study of 177 Cases.
    Atienza-Mateo B, Martín-Varillas JL, Calvo-Río V, Demetrio-Pablo R, Beltrán E, Sánchez-Bursón J, Mesquida M, Adan A, Hernández MV, Hernández-Garfella M, Valls-Pascual E, Martínez-Costa L, Sellas-Fernández A, Cordero-Coma M, Díaz-Llopis M, Gallego R, García-Serrano JL, Ortego-Centeno N, Herreras JM, Fonollosa A, Garcia-Aparicio ÁM, Maíz-Alonso O, Blanco A, Torre-Salaberri I, Fernandez-Espartero C, Jovaní V, Peiteado D, Pato E, Cruz J, Férnandez-Cid C, Aurrecoechea E, García-Arias M, Castañeda S, Caracuel-Ruiz MA, Montilla-Morales CA, Atanes-Sandoval A, Francisco F, Insua S, González-Suárez S, Sanchez-Andrade A, Gamero F, Linares Ferrando LF, Romero-Bueno F, García-González AJ, González RA, Muro EM, Carrasco-Cubero C, Olive A, Prior Á, Vázquez J, Ruiz-Moreno O, Jiménez-Zorzo F, Manero J, Muñoz Fernandez S, Fernández-Carballido C, Rubio-Romero E, Pages FA, Toyos-Sáenz de Miera FJ, Martinez MG, Díaz-Valle D, López Longo FJ, Nolla JM, Álvarez ER, Martínez MR, González-López JJ, Rodríguez-Cundin P, Hernández JL, González-Gay MA, Blanco R.
    Arthritis Rheumatol; 2019 Dec; 71(12):2081-2089. PubMed ID: 31237427
    [Abstract] [Full Text] [Related]

  • 5. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet's disease: an open-label trial.
    Tugal-Tutkun I, Mudun A, Urgancioglu M, Kamali S, Kasapoglu E, Inanc M, Gül A.
    Arthritis Rheum; 2005 Aug; 52(8):2478-84. PubMed ID: 16052571
    [Abstract] [Full Text] [Related]

  • 6. Long-term Follow-up and Optimization of Infliximab in Refractory Uveitis Due to Behçet Disease: National Study of 103 White Patients.
    Martín-Varillas JL, Atienza-Mateo B, Calvo-Rio V, Beltrán E, Sánchez-Bursón J, Adán A, Hernández-Garfella M, Valls-Pascual E, Sellas-Fernández A, Ortego N, Maíz O, Torre I, Fernández-Espartero C, Jovani V, Peiteado D, Valle DD, Aurrecoechea E, Caracuel MA, García-González AJ, Álvarez ER, Vegas-Revenga N, Demetrio-Pablo R, Castañeda S, González-Gay MA, Hernández JL, Blanco R, Ricardo Blanco on behalf of the Spanish Collaborative Group of Refractory Behçet’s Disease.
    J Rheumatol; 2021 May; 48(5):741-750. PubMed ID: 33004539
    [Abstract] [Full Text] [Related]

  • 7. Clinical background comparison of patients with and without ocular inflammatory attacks after initiation of infliximab therapy.
    Yoshida A, Kaburaki T, Okinaga K, Takamoto M, Kawashima H, Fujino Y.
    Jpn J Ophthalmol; 2012 Nov; 56(6):536-43. PubMed ID: 23053631
    [Abstract] [Full Text] [Related]

  • 8. The effect of biologic therapy different from infliximab or adalimumab in patients with refractory uveitis due to Behçet's disease: results of a multicentre open-label study.
    Santos-Gómez M, Calvo-Río V, Blanco R, Beltrán E, Mesquida M, Adán A, Cordero-Coma M, García-Aparicio ÁM, Valls Pascual E, Martínez-Costa L, Hernández MV, Hernandez Garfella M, González-Vela MC, Pina T, Palmou-Fontana N, Loricera J, Hernández JL, González-Gay MA.
    Clin Exp Rheumatol; 2016 Nov; 34(6 Suppl 102):S34-S40. PubMed ID: 27054359
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Anti-TNF-α Therapy for Refractory Uveitis Associated with Behçet's Syndrome and Sarcoidosis: A Single Center Study of 131 Patients.
    Kunimi K, Usui Y, Asakage M, Maehara C, Tsubota K, Mitsuhashi R, Umazume A, Kezuka T, Sakai JI, Goto H.
    Ocul Immunol Inflamm; 2022 Jan 02; 30(1):223-230. PubMed ID: 32815752
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Ten-Year Retention Rate of Infliximab in Patients with Behçet's Disease-Related Uveitis.
    Fabiani C, Sota J, Vitale A, Emmi G, Vannozzi L, Bacherini D, Lopalco G, Guerriero S, Venerito V, Orlando I, Franceschini R, Fusco F, Frediani B, Galeazzi M, Iannone F, Tosi GM, Cantarini L.
    Ocul Immunol Inflamm; 2019 Jan 02; 27(1):34-39. PubMed ID: 29099660
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Clinical Follow-up of Patients with Behçet Uveitis after Discontinuation of Infliximab Therapy.
    Köse HC, Yalçındağ N.
    Ocul Immunol Inflamm; 2022 Jan 02; 30(1):203-207. PubMed ID: 32779960
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.